undamentalytics Newsletter
Sign in

Veracyte, Inc. cash flow statement

In fiscal 2025, Veracyte, Inc.'s operations generated $136m of cash; it spent $9.7m on capital projects, leaving free cash flow of $127m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−14−7−19−28−27−28−24−14−3−10−3284475136178
Depreciation and amortisation1111244448202627232121
Stock-based pay——1466761013232733364449
Capital spending01126422335910111012
Free cash flow−14−9−20−30−33−32−26−15−6−13−37−13464127166
Free cash flow after stock pay——−22−33−39−39−32−21−16−26−60−2812883117

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AZTA vs VCYTTXG vs VCYTTWST vs VCYT

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Veracyte, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Veracyte, Inc.